Key result
Combined implantation of a CCM device and an S-ICD caused initial crosstalk that was safely resolved by reprogramming the CCM device.
Why the study?
Combined implantation of cardiac contractility modulation with a subcutaneous implantable cardioverter-defibrillator appears to be a suitable option to reduce intracardiac leads and complications, but potential device interactions need to be evaluated.
Does combined implantation of CCM and S-ICD cause device interference in patients with ischemic cardiomyopathy?
Case Report (n=1)
Does combined implantation of CCM and S-ICD cause device interference in patients with ischemic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Combined implantation of CCM and S-ICD is feasible and safe, provided that device interference is carefully tested and managed via reprogramming.
Combined implantation of cardiac contractility modulation (CCM) with subcutaneous implantable cardioverter-defibrillator (S-ICD) appears a suitable option to reduce the amount of intracardiac leads and complications for patients. Here we report on a patient with ischemic cardiomyopathy carrying an S-ICD in which a CCM device was implanted. During crosstalk testing post-CCM implantation, the S-ICD misannotated QRS complexes and T waves. The problem was solved through reprogramming the CCM, while preserving S-ICD functionality and improving heart failure symptoms. In conclusion, S-ICD combined with CCM seems to be a good and safe option for patients when device interference is being ruled out.
No takes yet. Share an insight, caveat, or question.
Trolese et al. (2021) conducted a case report in Ischemic cardiomyopathy (n=1). Cardiac contractility modulation (CCM) was evaluated. Combined implantation of a CCM device and an S-ICD caused initial crosstalk that was safely resolved by reprogramming the CCM device.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: